Companies · Other Health Care

LumiraDx Ltd

LONDON · Other Health Care

Diligence memoA one-page analyst read on LumiraDx Ltd — recommendation, valuation, rhythm, risks.
$779.1M
Total raised · real
7
Rounds
2.2×
Latest step-up
Top 1%
Sector rank · raised
Series D+
Latest stage · inferred · Mon Nov 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

LumiraDx Ltd looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.04× the median modeled value of Series D+ Other Health Care companies in 2019–2021 (26 peers) — value vs value, same stage and era.
  • Within the normal band (104% of peer median) for its niche.
Dormant
  • Last raise 5.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

LumiraDx Ltd is one of 5377 Other Health Care companies tracked from LONDON. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
31
Investors (latest)
2016
Year incorporated
2020-11-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5B$5.0B$7.5B$10.0BSeries C · 2016-10-03 Raised $43M (real) Modeled valuation $975M (est)Series C2016Series C · 2016-11-29 Raised $613K (real) Modeled valuation $14M (est)Series C2016Series C · 2017-11-28 Raised $77M (real) Modeled valuation $1.8B (est)Series C2017Series D+ · 2018-08-16 Raised $270M (real) Modeled valuation $6.2B (est)Series D+2018Series D+ · 2019-10-15 Raised $75M (real) Modeled valuation $1.7B (est)Series D+2019Series D+ · 2020-03-28 Raised $150M (real) Modeled valuation $3.5B (est)Series D+2020Series C · 2020-03-28 Raised $53M (real) Modeled valuation $1.2B (est)Series C2020Series C · 2020-03-28 Raised $53M (real) Modeled valuation $1.2B (est)Series C2020Series D+ · 2020-07-01 Raised $74M (real) Modeled valuation $1.7B (est)Series D+2020Series D+ · 2020-11-30 Raised $164M (real) Modeled valuation $3.5B (est)Series D+2020+$613K+$77M+$270M+$75M+$150M+$53M+$53M+$74M+$164MCumulative $958M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$42.6M · 2016
Series C extension$613K · 2016
Series C extension$76.7M · 2017
Series D+$270.0M · 2018
Series D+ extension$75.2M · 2019
Series D+ extension$150.0M · 2020
Bridge · Series D+-stage$52.5M · 2020smaller follow-on
Bridge · Series D+-stage$52.5M · 2020smaller follow-on
Series D+ extension$74.0M · 2020
Series D+ extension$164.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$3.5B
Base estimate est.
$873.6M
Conservative case
$7.2B
Upside case
$1.4B
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series C · modeled $974.5M · 2016-10-032016Series C · modeled $14.0M · 2016-11-29Series C · modeled $1.8B · 2017-11-28Series D+ · modeled $6.2B · 2018-08-16Series D+ · modeled $1.7B · 2019-10-15Series D+ · modeled $3.5B · 2020-03-28Series C · modeled $1.2B · 2020-03-28Series C · modeled $1.2B · 2020-03-28Series D+ · modeled $1.7B · 2020-07-01Series D+ · modeled $3.5B · 2020-11-302020
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
80%
Survival probability
64% low · 88% high
1.23×/yr
Annual markup
1.38×/yr upside case
5.6 yr
Elapsed time used
5.6 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$187.3M/yr
Capital velocity
9.7 yr
On record since
2016
First round
10
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 321× above median
This company$779.1M
Sector median$2.4M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 1.3× above median
This company$164.0M
Sector median$123.0M
Modeled value — vs sector median (estimate, all stages) 157× above median
This company$3.5B
Sector median$22.1M

Raised more than 100% of sector peers (real $). Modeled value above 99% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 26.

This companyCohort peer
$1.0B$10.0B$100.0M$1.0BCapital raised (log)ZAHN Parent, LLC · Series D+ Raised $379.9M · modeled $8.7B (est)Covetrus, Inc. · Series D+ Raised $361.1M · modeled $8.3B (est)EQH Parent, LLC · Series D+ Raised $334.2M · modeled $6.7B (est)SonerMed, LLC · Series D+ Raised $300.0M · modeled $6.7B (est)Fs Usme Lp · Series D+ Raised $282.0M · modeled $6.0B (est)Medable Inc. · Series D+ Raised $501.0M · modeled $5.4B (est)Cedar Cares, Inc. · Series D+ Raised $569.4M · modeled $5.1B (est)Inotiv, Inc. · Series D+ Raised $280.1M · modeled $4.8B (est)Magnolia (MH) Holdings, L.P. · Series D+ Raised $259.8M · modeled $4.4B (est)Orca BioSystems Inc · Series D+ Raised $192.0M · modeled $4.4B (est)eHealth, Inc. · Series D+ Raised $225.0M · modeled $4.4B (est)ECG Europe, Inc. · Series D+ Raised $200.0M · modeled $3.6B (est)LumiraDx Ltd (this company) Raised $779.1M · modeled $3.5B (est)LumiraDx Ltd
CompanyStageRaised · realValue · estvs peer med.
ZAHN Parent, LLCSeries D+$379.9M$8.7B2.64×
Covetrus, Inc.Series D+$361.1M$8.3B2.51×
EQH Parent, LLCSeries D+$334.2M$6.7B2.04×
SonerMed, LLCSeries D+$300.0M$6.7B2.02×
Fs Usme LpSeries D+$282.0M$6.0B1.80×
Medable Inc.Series D+$501.0M$5.4B1.63×
Cedar Cares, Inc.Series D+$569.4M$5.1B1.54×
Inotiv, Inc.Series D+$280.1M$4.8B1.45×
Magnolia (MH) Holdings, L.P.Series D+$259.8M$4.4B1.33×
Orca BioSystems IncSeries D+$192.0M$4.4B1.33×
eHealth, Inc.Series D+$225.0M$4.4B1.32×
ECG Europe, Inc.Series D+$200.0M$3.6B1.09×
LumiraDx Ltd this companySeries D+$779.1M$3.5B1.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$42.6M2016-10-03$284.2M$974.5M90%
Series C$613K2016-11-29$4.1M$14.0M90%
Series C$76.7M2017-11-28$511.2M$1.8B90%
Series D+$270.0M2018-08-16$2.3B$6.2B90%
Series D+$75.2M2019-10-15$626.3M$1.7B90%
Series D+$150.0M2020-03-28$1.3B$3.5B90%
Series C$52.5M2020-03-28$350.3M$1.2B90%
Series C$52.5M2020-03-28$350.3M$1.2B90%
Series D+$74.0M2020-07-01$616.7M$1.7B90%
Series D+$164.0M2020-11-30$1.4B$3.5B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$42.6M2016-10-03
    • First recorded raise — entered as Series C.
    • 2 investors on this round.
  2. Series C$613K2016-11-29
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 69.5× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  3. Series C$76.7M2017-11-28
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 125.0× larger than the prior — scaling up.
    • 188 investors on this round.
  4. Series D+$270.0M2018-08-16
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 3.5× larger than the prior — scaling up.
    • 256 investors on this round.
  5. Series D+$75.2M2019-10-15
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 3.6× smaller than the prior — bridge or down round.
    • 171 investors on this round.
  6. Series D+$150.0M2020-03-28
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 118 investors on this round.
  7. Series C$52.5M2020-03-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.9× smaller than the prior — bridge or down round.
    • 20 investors on this round.
  8. Series C$52.5M2020-03-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 20 investors on this round.
  9. Series D+$74.0M2020-07-01
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
  10. Series D+$164.0M2020-11-30
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
    • 31 investors on this round.
Intelligence
2021 ~Q2
Modeled next raise · ~6mo cadence
$363.5M
Modeled next size est.range $236.2M$581.5M
2.2×
Last step-up
$187.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gerald Chan12 other2020-11
David Scott11 other2016-10
RON ZWANZIGER5 other2016-10
David Walton2 other2016-10
Donald Berwick2 other2017-11
George Neble2 other2020-11
Jerry McAleer1 other2016-10
Lu Huang1 other2017-11
Peter Scheu1 other2017-11
Amit Thakker2020-11
Bruce Keogh2017-11
Dorian LeBlanc2017-11
Lurene Joseph2016-11
Nigel Lindner2016-10
Peter Welch2016-10
Sumit Nagpal2016-10
Suresh Vazirani2016-11
Tom Quinlan2017-11
Troy Brennan2016-11
Troyen Brennan2017-11
Veronique Ameye2016-10
Registry & provenance

LumiraDx Ltd is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1685428
SEC CIK
2016
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Alere Inc.Other Health CareSeries D+$500.0M$9.2Bnetwork5 shared operators · same sector · same stage
ElectraDx, Inc.Other Health CareSeries A$14.8M$80.8Mnetwork2 shared operators · same sector
American Well CorpOther Health CareSeries D+$755.5M$1.1Bsame sector · same stage
DispatchHealth Holdings, Inc.Other Health CareSeries D+$578.0M$3.7Bsame sector · same stage
Cedar Cares, Inc.Other Health CareSeries D+$569.4M$5.1Bsame sector · same stage
Medable Inc.Other Health CareSeries D+$501.0M$5.4Bsame sector · same stage
Endologix Inc /De/Other Health CareSeries D+$420.0M$4.8Bsame sector · same stage
Coding Solutions Topco, Inc.Other Health CareSeries D+$376.3M$588.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Lumonus Pty LtdOther Health CarePre-Seed$1.5M88%
Luminus Holdings CorpOther Health CareSeries A$100.9M86%
PrismHealthDX, Inc.Other Health CareSeries A$113.0M86%
MedRx Global, Inc.Other Health CarePre-Seed$27.7M85%
Luminopia, Inc.Other Health CareSeries B$142.2M85%
FundRx, Inc.Other Health CareSeed$34.5M84%
Lumati Holdings, LLCOther Health CareSeed$7.0M84%
Dermira, Inc.Other Health CareSeries C$22.9M84%
Frequently asked
How much funding has LumiraDx Ltd raised?
LumiraDx Ltd has raised approximately $779.1M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is LumiraDx Ltd's estimated valuation?
Provath's modeled valuation for LumiraDx Ltd is approximately $3.5B (modeled range $873.6M–$7.2B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is LumiraDx Ltd at?
LumiraDx Ltd's latest modeled financing stage is Series D+. Its most recent recorded round closed around Mon Nov 30.
What does LumiraDx Ltd do and where is it based?
LumiraDx Ltd operates in the Other Health Care sector, based in LONDON.
Explore related

See where LumiraDx Ltd sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at LumiraDx Ltd, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.